SCHEMBL29361900

SCHEMBL29361900

CCCCCn1cc(C(=O)c2cccc3ccccc23)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 15/20 1.00
CNR1 P21554 7/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1707018 1.00 CNR2 (1.00) CNR2CNR1
SCHEMBL16201691 0.99 CNR2 (0.98) CNR2CNR1
SCHEMBL16201689 0.99 CNR2 (0.98) CNR2CNR1
SCHEMBL29988966 0.99 CNR2 (0.98) CNR2CNR1
SCHEMBL29362566 0.99 CNR2 (0.98) CNR2CNR1
SCHEMBL11983320 0.96 CNR2 (1.00) CNR2CNR1
SCHEMBL29375790 0.96 CNR2 (1.00) CNR2CNR1
SCHEMBL6325191 0.91 CNR2 (1.00) CNR2CNR1
SCHEMBL29988839 0.91 CNR2 (1.00) CNR2CNR1
SCHEMBL6324025 0.89 CNR2 (1.00) CNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 451 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122072257-A Method for rapidly detecting poison in blood 中国科学院大连化学物理研究所 2026-05-22 CN claimed
EP-4722714-A1 SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) Korea Institute of Science and Technology (KR) 2026-04-08 EP claimed
US-20250360137-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES FREEDOM BIOSCIENCES INC (US) 2025-11-27 US claimed
EP-4618980-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES Freedom Biosciences, Inc. (US) 2025-09-24 EP claimed
WO-2025137591-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING ZINC SOLUBILIZATION AND ZINC UPTAKE IN PLANTS Tenfold Technologies, LLC (US) 2025-06-26 WO claimed
US-20250177506-A1 VACCINATION AND ANTIBODY GENERATION PLATFORM Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2025-06-05 US claimed
CN-119757587-A Method for determining 15 new psychoactive substances in saliva by SLE-UPLC-MS/MS 福州国际旅行卫生保健中心(福州海关口岸门诊部) 2025-04-04 CN claimed
EP-4486336-A2 CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF Adarx Pharmaceuticals, Inc. (US) 2025-01-08 EP claimed
CN-119136797-A CB1Ligand conjugated compounds and uses thereof 阿达尔克斯制药有限公司 2024-12-13 CN claimed
CN-115728280-B On-site detection method for synthesizing cannabinoid JWH-018 中国科学院新疆理化技术研究所 2024-09-24 CN claimed
CN-115144489-A Application of virtual template molecularly imprinted polymer in detection of synthesized casitone drugs 大连海事大学 2022-10-04 CN claimed
CN-114945353-A Controlled release formulations of highly lipophilic physiologically active substances 埃德先进药物输送技术有限责任公司 2022-08-26 CN claimed
CN-114942239-A Composition, kit and method for rapidly detecting synthetic cannabinoid in tobacco tar 合肥市公安局刑事警察支队 2022-08-26 CN claimed
EP-4045007-A1 CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES ADD Advanced Drug Delivery Technologies, Ltd. (CH) 2022-08-24 EP claimed
EP-4045014-A1 CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES ADD Advanced Drug Delivery Technologies, Ltd. (CH) 2022-08-24 EP claimed
CN-114929197-A Controlled release formulations of highly lipophilic physiologically active substances 埃德先进药物输送技术有限责任公司 2022-08-19 CN claimed
EP-4041748-A1 PEPTIDE COMPOUNDS FOR REDUCING SIDE EFFECTS OF CB1 RECEPTOR AGONISTS Universitat de Barcelona (ES) 2022-08-17 EP claimed
CN-114641486-A For reducing CB1Peptide compounds of side effects of receptor agonists 庞培法布拉大学 2022-06-17 CN claimed
CN-114414548-A SERS substrate and application thereof 安徽中科赛飞尔科技有限公司 2022-04-29 CN claimed
US-20220117932-A1 Lecithin Vesicles CannaClear Inc. (CA) 2022-04-21 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250360137-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES PDE9A, PDE3A, PDE2A CNR2 204/4885CNR1 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.